Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
US Department of Justice
UBS
Farmers Insurance
Mallinckrodt
AstraZeneca
Cipla
Fuji
Chinese Patent Office

Generated: December 12, 2018

DrugPatentWatch Database Preview

XADAGO Drug Profile

« Back to Dashboard

When do Xadago patents expire, and when can generic versions of Xadago launch?

Xadago is a drug marketed by Us Worldmeds Llc and is included in one NDA. There are three patents protecting this drug.

This drug has ninety patent family members in thirty-one countries.

The generic ingredient in XADAGO is safinamide mesylate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the safinamide mesylate profile page.

Summary for XADAGO
Drug patent expirations by year for XADAGO
Generic Entry Opportunity Date for XADAGO
Generic Entry Date for XADAGO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Synonyms for XADAGO
(+-)-(S)-2-((p-((m-Fluorobenzyl)oxy)benzyl)amino)propionamide
(2''S'')-2-[[4-[(3-Fluorophenyl)methoxy]phenyl] methylamino]propanamide
(2S)-2-[({4-[(3-fluorophenyl)methoxy]phenyl}methyl)amino]propanamide
(2S)-2-[[4-[(3-Fluorophenyl)methoxy]phenyl]methylamino]propanamide
(5)-2-[4-(3-fluorobenzyloxy)benzylamino]propanamide
(S)-(+)-2-[4-(3-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDE METHANSULFONATE
(S)-2-(((4-((3-Fluorophenyl)methoxy)phenyl)methyl)amino)propanamide
(S)-2-((4-((3-Fluorobenzyl)oxy)benzyl)amino)propanamide
(S)-2-[[4-[(3-Fluorobenzyl)oxy]benzyl]amino]propionamide
(S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide; compound with methanesulfonic acid
(S)-2-[4-(3-fluorobenzyloxy)benzylamino]propanamide
(S)-2[4-(3-fluorobenzyloxy)benzylamino] propanamide
(S)-2[4-(3-fluorobenzyloxy)benzylamino]propanamide
133865-89-1
2-(4-(3-Fluorobenzyloxy)benzylamino)propionamide
2(s)-(4-(3-fluorobenzyloxy)benzylamino)propionamide
6135AA
90ENL74SIG
AC-26829
AC1L2ZLK
AJ-112157
AK-77847
AKOS016002015
ANW-58666
API0009223
AX8150732
BC224413
BDBM19187
BDBM50078694
CHEBI:134718
CHEMBL396778
CHEMBL48582
CS-0556
CTK8B7808
D02MOK
D0TV6I
D10158
DB06654
EC 603-772-2
EMD 1195686
EMD-1195686
Fce 26743
Fce-26743
FT-0700949
GTPL8291
HY-70057
J-506604
M6252
MolPort-005-942-375
N2-(4-((3-Fluorbenzyl)oxy)benzyl)-L-alaninamid
N2-{4-[(3-fluorobenzyl)oxy]benzyl}-L-alaninamide
NCGC00346529-01
NEMGRZFTLSKBAP-LBPRGKRZSA-N
ON 019190.Na
P111001
Propanamide, 2-(((4-((3-fluorophenyl)methoxy)phenyl)methyl)amino)-, (S)-
RL01540
S0935
Safinamide
Safinamide (USAN/INN)
Safinamide [USAN:INN]
safinamide methanesulfonate
SAFINAMIDE: - -2-[4- BENZYLAMINO]PROPANAMIDEMETHANSULFONATE
SC-89769
SCHEMBL69350
ST24035822
TC-147411
UNII-90ENL74SIG
W-5197
ZINC53084692

US Patents and Regulatory Information for XADAGO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Us Worldmeds Llc XADAGO safinamide mesylate TABLET;ORAL 207145-001 Mar 21, 2017 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Us Worldmeds Llc XADAGO safinamide mesylate TABLET;ORAL 207145-002 Mar 21, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Us Worldmeds Llc XADAGO safinamide mesylate TABLET;ORAL 207145-001 Mar 21, 2017 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Us Worldmeds Llc XADAGO safinamide mesylate TABLET;ORAL 207145-002 Mar 21, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for XADAGO

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015 00042 Denmark ➤ Sign Up PRODUCT NAME: KOMBINATION AF SAFINAMID, HERUNDER SAFINAMID METHANSULFONAT, OG LEVODOPA/PDI; REG. NO/DATE: EU/1/14/984/001-010 20150226
782 Luxembourg ➤ Sign Up PRODUCT NAME: SAFINAMIDE A UTILISER EN COMBINAISON AVEC LEVODOPA/PDI, ET EVENTUELLEMENT AVEC D'AUTRES MEDICAMENTS PD , POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON; FIRST REGISTRATION DATE: 20150224
0752 Netherlands ➤ Sign Up PRODUCT NAME: SAFINAMIDE; REGISTRATION NO/DATE: EU/1/14/984 20150224
2015 00042 Denmark ➤ Sign Up PRODUCT NAME: KOMBINATION AF SAFINAMID OG LEVOPODA/PDI; REG. NO/DATE: EU/1/14/984/001-010 20150224
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Deloitte
UBS
Express Scripts
Farmers Insurance
Covington
McKinsey
Teva
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.